All In Biotech

Drug Trial Radar · NCT06134271

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

A Multicenter, Prospective, Cohort Study on the Treatment of Metastatic Hormone-sensitive Prostate Cancer Patients Who Have Progressed After Pre-treatment With Rezvilutamide Combined With Abiraterone

Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 15, 2023

Primary completion

Apr 30, 2025

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Jianbin BiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order chemotherapy alone or bicalutamide); To observe the efficacy and safety of rezvilutamide alone or in combination with abiraterone in hormone-sensitive prostate cancer patients with PSA progression following prior sequence therapy.

Conditions

  • Metastatic Hormone-Sensitive Prostate Cancer

Interventions

  • RezvilutamideDrug

    Rezvilutamide 240mg qd

  • Rezvilutamide plus abirateroneDrug

    Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd

  • Continue previous treatmentDrug

    Continue using the previous treatment regimen for treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to castration-resistant prostate cancer (CRPC)Time frame: From the first day of patient enrollment until the time reach CRPC, the duration of the assessment should not exceed 24 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.